On Tuesday, U.S. stocks experienced a positive trading session. The Dow Jones Industrial Average climbed over 480 points, ...

Successful management of denture-associated candidiasis relies heavily on mechanical disinfection rather than pharmacologic ...

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...

Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence ...

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...

Alumis, a clinical-stage biopharmaceutical company, has announced two phase 3 trials of its TYK2 inhibitor envudeucitinib met ...

Alumis said on Tuesday its experimental drug met the main goal of improving symptoms of a common skin disease in two late-stage studies, powering its shares to a record high and more than doubling ...

Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...

Psoriasis is a chronic, recurrent, and incurable autoimmune disease in which the body mistakenly attacks its own tissue, ...

Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...